参考文献

［1］　中华医学会心血管分会心力衰竭学组，中国医师协会心力衰竭专业委员会.心力衰竭诊断和治疗指南2018［J］.中华心血管病杂志，2018，46：760-783.

［2］　霍勇.心力衰竭合理用药指南［J］.中国医学前沿杂志，2019，11：（7）25-55.

［3］　Yancy CW，Jessp M，Bozkrt B，et al.2017 ACC／AHA／HFSA focused update of the 2013 ACCF／AHA guideline for the management of heart failure：A report of the American College of Cardioloy／American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America［J］.Circulation，2017，136：el37-e161.

［4］　Nishimura RA，Otto CM，Bonow RO，et al.2017 AHA／ACC focused update of the 2014 AHA／ACCguideline for the management of patients with valvular heartdisease：A report of the American College of Cardiology／American Heart Association Task Forceon Clinical Practice Guidelines［J］.Circulation，2017，135（25）：e1159-1195.

［5］　Kosiborod M，Lam CSP，Kohsaka S，et al.Cardiovascular events associated with SGLT2 inhibitors versus other glucose-lowering drugs：The CVD-REAL 2 Study［J］.J Am Coll Cardiol，2018，71（23）：2628-2639.

［6］　Gupta VK，Brauneis D，Shelton AC，et al.Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for AL amyloidosis：Long-term follow-up analysis［J］.Biology of Blood and Marrow Transplantation，2019，25（5）：e169-e173.(https://www.daowen.com)

［7］　托伐普坦临床研究协作组.常规治疗基础上联用托伐普坦片治疗心源性水肿的有效性和安全性的多中心随机、双盲、安慰剂对照研究［J］.中华心力衰竭和心肌病杂志（中英文），2017，1（1）：15-21.

［8］　Fitchett D，Butler J，van de Borne P，et al.Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial［J］.Eur Heart J，2018，39：363-370.

［9］　Kosiborod M，Cavender MA，Fu AZ，et al.Lower risk of heart failure and death in patients initiated on sodiumglucose cotransporter-2 inhibitors versus other glucose-lowering drugs：The CVD-REAL study（comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors）［J］.Circulation，2017，136：249-259.

［10］　Kosiborod M，Lam CSP，Kohsaka S，et al.Lower Cardiovascular risk associated with SGLT2 in ＞400000 patients：The CVD-REAL 2 Study［J］.J Am Coll Cardiol，2018，71（23）：2628-2639.

［11］　Verma S，Mazer CD，Fitchett D，et al.Empagliflozin reduces cardiovascular events，mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery：subanalysis of the EMPA-REG OUTCOME randomised trial［J］.Diabetologia，2018，61：1712-1723.